Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

PD 198306

Copy Product Info
😃Good
Catalog No. T21980Cas No. 212631-61-3

PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1.

PD 198306

PD 198306

Copy Product Info
😃Good
Purity: 99.66%
Catalog No. T21980Cas No. 212631-61-3
PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$58In StockIn Stock
5 mg$141In StockIn Stock
10 mg$198In StockIn Stock
25 mg$348In StockIn Stock
50 mg$497In StockIn Stock
100 mg$690In StockIn Stock
500 mg$1,360-In Stock
1 mL x 10 mM (in DMSO)$163In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.66%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1.
In vitro
PD 198306 (10 μM) reduces Tha-Crimson replication by 30% at 18 h and 50% at 36 h. PD 198306 (10  μM) significantly inhibits Tha-GFP replication by 25%[1].
In vivo
In male Sprague Dawley rats bearing neuropathic pain, PD 198306 (1-30 μg/10 μL; i.t.) dose-dependently blocks static allodynia in both the chronic constriction injury and the streptozocin models[2].
Chemical Properties
Molecular Weight476.23
FormulaC18H16F3IN2O2
Cas No.212631-61-3
SmilesN(C1=C(C(NOCC2CC2)=O)C=C(F)C(F)=C1F)C3=C(C)C=C(I)C=C3
Relative Density.1.686g/cm3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 45 mg/mL (94.49 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.5 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.0998 mL10.4991 mL20.9983 mL104.9913 mL
5 mM0.4200 mL2.0998 mL4.1997 mL20.9983 mL
10 mM0.2100 mL1.0499 mL2.0998 mL10.4991 mL
20 mM0.1050 mL0.5250 mL1.0499 mL5.2496 mL
50 mM0.0420 mL0.2100 mL0.4200 mL2.0998 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy PD 198306 | purchase PD 198306 | PD 198306 cost | order PD 198306 | PD 198306 chemical structure | PD 198306 in vivo | PD 198306 in vitro | PD 198306 formula | PD 198306 molecular weight